CAMBRIDGE,
Mass., Sept. 2, 2021 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC) today announced that
Kate Haviland, Blueprint Medicines'
Chief Operating Officer, and Fouad Namouni, M.D., Blueprint
Medicines' President, Research & Development, will participate
virtually in a fireside chat at the Morgan Stanley 19th
Annual Global Healthcare Conference on Thursday, September 9, 2021 at 12:30 p.m. ET.
A live webcast of the presentation will be
available by visiting the Investors & Media section
of Blueprint Medicines' website
at http://ir.blueprintmedicines.com. A replay of the webcast
will be archived on Blueprint Medicines' website for 30
days following the presentation.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy
company that invents life-changing therapies for people with cancer
and hematologic disorders. Applying an approach that is both
precise and agile, we create medicines that selectively target
genetic drivers, with the goal of staying one step ahead across
stages of disease. Since 2011, we have leveraged our research
platform, including expertise in molecular targeting and
world-class drug design capabilities, to rapidly and reproducibly
translate science into a broad pipeline of precision therapies.
Today, we are delivering approved medicines directly to patients in
the United States and Europe, and we are globally advancing multiple
programs for genomically defined cancers, systemic mastocytosis,
and cancer immunotherapy. For more information,
visit www.BlueprintMedicines.com and follow us
on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-morgan-stanley-19th-annual-global-healthcare-conference-301366780.html
SOURCE Blueprint Medicines Corporation